Skip to main content

Table 2 Treatment arms and confirmed prognostic factors in studies included in the meta-analysis (n = 17)

From: Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors

Author, year

Study arms

Confirmed prognostic factors

Robak 2010 [16]

FCR vs FC

None

Hallek 2010 [17]

FCR vs FC

Del(17p), B2M, WCC, unmutated IGHV

Goede 2014 [15]

R-Chl vs Chl

O-Chl vs Chl

None

Chanan-khan 2016 [46]

IBR vs Placebo-BR

None

Van Oers 2015 [51]

M-OFA vs OBS

None

Hillmen 2015 [47]

O-Chl vs Chl

None

Robak 2017 [42]

OFA + FC vs FC

None

Greil 2016 [44]

MR vs OBS

None

Dartigeas 2017 [45]

MR vs OBS

Unmutated IGHV

Robak 2018 [43]

MR vs OBS

Del(17p), Del(11q), elevated B2M

Woyach 2018 [14]

IR vs Ibr

Age, Del(17p), LDH

Seymour 2018 [40]

VenR vs BR

None

Moreno 2019 [48]

I-O vs O-Chl

None

Fischer 2019 [49]

Ven-O vs O-Chl

None

Shanafelt 2019 [39]

IR vs FCR

None

Sharman 2020 [50]

Acala vs Chl-O

None

Ghia 2020 [41]

Acala vs BR

None

  1. FCR Fludarabine, cyclophosphamide plus rituximab, Chl Chlorambucil, O-Chl Obinutuzumab plus chlorambucil, IBR Ibrutinib plus bendamustine and rituximab, M-OFA Ofatumumab maintenance, acala acalabrutinib, MR rituximab maintenance, OBS Observation, IR Ibrutinib plus rituximab, Ibr Ibrutinib, Ven-O Venetoclax plus Obinutuzumab, WCC White cell count, LDH Lactate dehydrogenate, IGHV Immunoglobulin heavy chain variable region gene, B2M Beta-2-microglobulin, Del- Deletion